Portal de investigación
Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Reina-Castillon, J
- Pujol, R
- Lopez-Sanchez, M
- Rodriguez-Santiago, B
- Aza-Carmona, M
- Ramon Gonzalez, Juan
- Antonio Casado, Jose
- Antonio Bueren, Juan
- Sevilla, J
- Badel, I
- Catala, A
- Belendez, C
- Diaz de Heredia, Cristina
- Soulier, J
- Schindler, D
- Alberto Perez-Jurado, Luis
- Surralles, J
Grupos
Abstract
Detectable clonal mosaicism for large chromosomal events has been associated with aging and an increased risk of hematological and some solid cancers. We hypothesized that genetic cancer predisposition disorders, such as Fanconi anemia (FA), could manifest a high rate of chromosomal mosaic events (CMEs) in peripheral blood, which could be used as early biomarkers of cancer risk. We studied the prevalence of CMEs by single-nucleotide polymorphism (SNP) array in 130 FA patients' blood DNA and their impact on cancer risk. We detected 51 CMEs (4.4-159 Mb in size) in 16 out of 130 patients (12.3%), of which 9 had multiple CMEs. The most frequent events were gains at 3q (n = 6) and 1q (n = 5), both previously associated with leukemia, as well as rearrangements with breakpoint clustering within the major histocompatibility complex locus (P = 7.3 x 10(-9)). Compared with 15 743 age-matched population controls, FA patients had a 126 to 140 times higher risk of detectable CMEs in blood (P < 2.2 x 10(-16)). Prevalent and incident hematologic and solid cancers were more common in CME carriers (odds ratio [OR] = 11.6, 95% confidence interval [CI] = 3.4-39.3, P = 2.8 x 10(-5)), leading to poorer prognosis. The age-adjusted hazard risk (HR) of having cancer was almost 5 times higher in FA individuals with CMEs than in those without CMEs. Regarding survival, the HR of dying was 4 times higher in FA individuals having CMEs (HR = 4.0, 95% CI = 2.0-7.9, P = 5.7 x 10(-5)). Therefore, our data suggest that molecular karyotyping with SNP arrays in easy-to-obtain blood samples could be used for better monitoring of bone marrow clonal events, cancer risk, and overall survival of FA patients.
Datos de la publicación
- ISSN/ISSNe:
- 2473-9529, 2473-9537
- Tipo:
- Article
- Páginas:
- 319-329
Blood Advances AMER SOC HEMATOLOGY
Citas Recibidas en Web of Science: 17
Documentos
- No hay documentos
Filiaciones
Proyectos asociados
AVANCES EN EL ESTUDIO DE LA REACTIVIDAD PLAQUETARIA Y SU INTERACCION CON LOS ERITROCITOS: BASES MOLECUALRES Y APLICABILIDAD CLINICO-FARMACOLOGICA
Investigador Principal: JUANA VALLES GINER
PI03/0270 . INSTITUTO DE SALUD CARLOS III . 2004
NUEVOS ASPECTOS DE LAS BASES BIOQUIMICAS, FUNCIONALES Y MOLECULARES DE AL REACTIVIDAD DE LAS PLAQUETAS Y SU INTERACCION CON LOS ERITROCITOS. APLICABILIDAD EN EL TRATAMIENTO CON FARMACOS ANTIPLAQUETARIOS.
Investigador Principal: MARIA TERESA SANTOS DIAZ
PI07/0463 . INSTITUTO DE SALUD CARLOS III . 2007
COMPREHENSIVE, INTEGRATIVE AND GENOMIC APPROACH TO THE UNDERSTANDING AND TREATMENT OF CANCER AND LEUKEMIA.
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
PIE13/00046 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
ENSAYO CLÍNICO MULTICÉNTRICO, ALEATORIZADO, ABIERTO, CONTROLADO CON COMPARADOR ACTIVO, PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE RIVAROXABAN A UN RÉGIMEN DE DOSIS AJUSTADO SEGÚN LA EDAD Y EL PESO, EN NIÑOS CON TROMBOEMBOLISMO VENOSO AGUDO.
Investigador Principal: MARÍA DE LOS ÁNGELES DASI CARPIO
BAY59-7939/14372 . 2014
ENSAYO CLÍNICO ALEATORIZADO, ABIERTO, CONTROLADO CON COMPARADOR ACTIVO, PARA EVALUAR LA SEGURIDAD, LA EFICACIA Y LAS PROPIEDADES FARMACOCINÉTICAS Y FARMACODINÁMICAS DE RIVAROXABAN ORAL, DURANTE 30 DÍAS DE TRATAMIENTO, EN NIÑOS CON MANIFESTACIONES DIVERSAS DE TROMBOSIS VENOSA.
Investigador Principal: MARÍA DE LOS ÁNGELES DASI CARPIO
BAY59-7939/14374 . 2014
ESTUDIO DE DOS PARTES, DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO Y ABIERTO PARA INVESTIGAR LA EFICACIA, SEGURIDAD Y TOLERABILIDAD DE ELTROMBOPAG, UN AGONISTA DEL RECEPTOR DE LA TROMBOPOYETINA, EN SUJETOS PEDIÁTRICOS CON PÚRPURA TROMBOCITOPÉNICA IN MUNE (IDIOPÁTICA) (PTI) CRÓNICA PREVIAMENTE TRATADOS.
Investigador Principal: MARÍA DE LOS ÁNGELES DASI CARPIO
TRA115450
Cita
Reina J,Pujol R,Lopez M,Rodriguez B,Aza M,Ramon J,Antonio J,Antonio J,Sevilla J,Badel I,Catala A,Belendez C,Angeles M,Diaz de Heredia C,Soulier J,Schindler D,Alberto Perez L,Surralles J. Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia. Blood Adv. 2017. 1. (5):p. 319-329.